Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.52 USD | -1.39% | -10.70% | +49.77% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.77% | 1.33B | |
+9.88% | 118B | |
+10.04% | 106B | |
-11.11% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.69% | 15.97B | |
+6.80% | 14.03B | |
+17.87% | 11.67B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12